AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21170697
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg EPs 7630 daily
Trial: 21170697
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg EPs 7630 daily
Trial: 21170697
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg EPs 7630 daily
Trial: 17191265
Drug: Standard olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard olanzapine tablets
Trial: 12005078
Drug: Heptavalent CRM197
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent CRM197 pneumococcal conjugate vaccine (PCV)
Trial: 7659241
Drug: Low-cost, technician-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cost, technician-administered anxiety reduction intervention (removing heart rate feedback, cognitive distraction, controlled breathing techniques)
Trial: 57448
Drug: Oestrogen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen treatment for five years
Trial: 57448
Drug: Delayed onset
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Oncet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed onset of oestrogen treatment (3 to 6 years)
Trial: 31035474
Drug: Tomato Nutrient
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato Nutrient Complex (TNC) 15 mg lycopene
Trial: 31035474
Drug: Tomato Nutrient
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato Nutrient Complex (TNC) 30 mg lycopene
Trial: 31035474
Drug: Tomato Nutrient
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato Nutrient Complex (TNC) 5 mg lycopene
Trial: 31035474
Drug: Synthetic lycopene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic lycopene 15 mg
Trial: 23863812
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg and Valsartan 160 mg
Trial: 23863812
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg and placebo
Trial: 23863812
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg and placebo
Trial: 21592232
Drug: Tadalafil 5mg
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil 5mg daily for 12 weeks
Trial: 21592232
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin 5mg daily for 12 weeks
Trial: 19628740
Drug: Serum concentrations
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum concentrations of L
Trial: 12807578
Drug: Recreational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational therapy (C)
Trial: 10969220
Drug: Continuous nebulization
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulization of salbutamol (15 mg during the first hour and 12.5 mg over the next 5 hours)
Trial: 10969220
Drug: Intermittent nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulization of salbutamol (5 mg every 20 minutes during the first hour and 2.5 mg hourly over the next 5 hours)
Trial: 1535588
Drug: Dopamine (D)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (D) and Glyceroltrinitrate (G)
Trial: 6387965
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 50 mg + Sotalol (STL) 320 mg
Trial: 30264419
Drug: Behavioural activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural activation therapy
Trial: 30264419
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help therapy
Trial: 23352379
Drug: Sitagliptin 25
RxNorm normalized name: SITagliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 25 mg daily
Trial: 23352379
Drug: Glipizide (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (initiated with 2.5 mg daily, titrated up to 10 mg twice daily)
Trial: 18548148
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in daily sodium intake of 1840 mg/day
Trial: 18548148
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in dietary sodium from 1200 mg/day to 2400 mg/day
Trial: 16570051
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 10,000‐20,000 IU three times weekly plus best standard treatment (BST)
Trial: 16570051
Drug: Best standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best standard treatment (BST) only
Trial: 12755663
Drug: Conventional antipsychotics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotics, olanzapine, risperidone
Trial: 11761770
Drug: 5,000 IU
RxNorm normalized name: bleopmycin 15,000 IU Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU of retinyl palmitate and 30 mg of beta-carotene daily during pregnancy; 200,000 IU of retinyl palmitate at delivery
Trial: 23183528
Drug: Sofosbuvir 100
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir 100 mg + PegIFN/RBV
Trial: 23183528
Drug: Sofosbuvir 200
RxNorm normalized name: sofosbuvir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 200 mg + PegIFN/RBV
Trial: 23183528
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg + PegIFN/RBV
Trial: 14603503
Drug: Untreated drug
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated drug
Trial: 10710409
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of ferrous sulfate (S) per day for 6 weeks
Trial: 8229720
Drug: Topical 0.03%
RxNorm normalized name: tacrolimus topical 0.03% topical ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.03% flurbiprofen sodium
Trial: 3101821
Drug: Respiratory health
RxNorm normalized name: HERBAL RESPIRATORY HEALTH CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory health worker visits (monthly by a respiratory nurse)
Trial: 27592092
Drug: Severe renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe renal dysfunction (GFR ≤30 mL/min)
Trial: 27592092
Drug: Moderate renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate renal dysfunction (GFR 31 to 60 mL/min)
Trial: 27592092
Drug: None/mild renal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None/mild renal dysfunction (GFR >60 mL/min)
Trial: 24015965
Drug: Weekly Sealed
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly Sealed (WS) pedometer group
Trial: 24015965
Drug: Daily Sealed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Sealed (DS) pedometer group
Trial: 2467983
Drug: Nalbuphine hydrochloride
RxNorm normalized name: Nalbuphine Hydrochloride
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine hydrochloride (0.375, 0.75, 1.5, 3 and 6 mg)
Trial: 2467983
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (0.1 and 0.2 mg)
Trial: 2467983
Drug: Hydromorphone hydrochloride
RxNorm normalized name: Hydromorphone Hydrochloride
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone hydrochloride (4 and 8 mg)
Trial: 322672
Drug: Carpipramine 3
RxNorm normalized name: carpipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carpipramine 3 X 50 mg per day for 8 weeks
Trial: 30367519
Drug: Omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA supplementation (2,120 mg eicosapentaenoic acid/600 mg docosohexaenoic acid)
Trial: 23151431
Drug: Short-term androgen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term androgen suppression (STAS) with leuprorelin (22.5 mg every 3 months)
Trial: 23151431
Drug: Intermediate-term androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-term androgen suppression (ITAS) with leuprorelin (22.5 mg every 3 months)
Trial: 23151431
Drug: ITAS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITAS plus zoledronic acid (4 mg every 3 months)
Trial: 18545204
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (25-g supplement)
Trial: 16190917
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg donepezil daily for 4 weeks
Trial: 16190917
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg donepezil daily for 8 weeks
Trial: 16190917
Drug: Post-drug discontinuation
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-drug discontinuation
Trial: 7777104
Drug: Erythropoietin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin therapy without iron supplementation (Group 3)
Trial: 7777104
Drug: Erythropoietin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin therapy with iron supplementation (Group 4)
Trial: 111943
Drug: Oral fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat load (100 g triglyceride) alone
Trial: 111943
Drug: Oral fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat load (100 g triglyceride) plus intravenous glucose infusion (0.7 g/kg/h)
Trial: 111943
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose infusion (0.7 g/kg/h)
Trial: 26156921
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea gargling solution (30 cc, gargled every 6 hours for 24 hours)
Trial: 26156921
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water gargling (30 cc, gargled every 6 hours for 24 hours)
Trial: 23354336
Drug: 0.7 g·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g·kg(‐1) mannitol (group L)
Trial: 23354336
Drug: 1.4 g·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g·kg(‐1) mannitol (group H)
Trial: 20850351
Drug: Intraoperative S(+)‐ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative S(+)‐ketamine (0.5 mg/kg as a preincisional bolus followed by a continuous infusion 400 μg/kg/h)
Trial: 20850351
Drug: Perioperative parexocib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Perioperative parexocib (40 mg before extubation and 12 hours postoperatively)
Trial: 20850351
Drug: Ropivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine alone (subpleural paravertebral infusion)
Trial: 19252905
Drug: Sodium ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ibuprofen (512 mg, equivalent to 400 mg ibuprofen acid)
Trial: 19252905
Drug: Ibuprofen/poloxamer (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/poloxamer (400 mg ibuprofen acid and 120 mg poloxamer 407)
Trial: 19252905
Drug: Sodium ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ibuprofen
Trial: 19252905
Drug: Ibuprofen/poloxamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/poloxamer
Trial: 19252905
Drug: Sodium ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ibuprofen and Ibuprofen/poloxamer
Trial: 17203352
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg given 30 min to 1 hour before biopsy
Trial: 17203352
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg given immediately after biopsy
Trial: 15879863
Drug: Doxazosin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (0.5 mg)
Trial: 9623433
Drug: Propofol 6
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 6 mg kg‐1 h‐1
Trial: 8151903
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for patients with clinically significant LV systolic dysfunction (LV ejection fraction <40%)
Trial: 8151903
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for patients with LV dysfunction and normal LV ejection fraction (diastolic dysfunction)
Trial: 3045470
Drug: 5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Gy fractional dose
Trial: 27171537
Drug: Perceptive rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceptive rehabilitation treatment with Surfaces for Perceptive Rehabilitation (Su‐Per)
Trial: 27171537
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group physical therapy treatment
Trial: 22188731
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose extrafine BDP/F 100/6 μg (1 actuation)
Trial: 22188731
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose extrafine BDP/F 100/6 μg (4 actuations)
Trial: 10992535
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose inhaled steroids plus low dose theophylline (LDT, 400 mg daily)
Trial: 10992535
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose inhaled steroids (LDS, 200 microgram BDP twice daily)
Trial: 10992535
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inhaled steroids (HDS, 500 microgram BDP)
Trial: 6318647
Drug: Postoperative chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy, radiotherapy, or a combination of both (95% of patients treated according to a randomized trial)
Trial: 27009278
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation 5 g/day for 8 weeks
Trial: 27009278
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil (CO) control 5 g/day for 8 weeks
Trial: 24293371
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of blood cholesterol lowering drugs during resistance exercise training
Trial: 16027408
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily for 4 days
Trial: 16027408
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin chloride 10 mg/d
Trial: 16027408
Drug: Extended-release tolterodine
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tolterodine tartrate 4 mg/d
Trial: 11684077
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of micronised fenofibrate
Trial: 9848522
Drug: Soy-protein powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-protein powder at 0, 5, 10, and 20 g/d (0-36 mg isoflavones)
Trial: 8017467
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg once daily at night
Trial: 25399847
Drug: Dual Antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual Antiplatelet Therapy Study participants
Trial: 11393342
Drug: Imidapril 5-20
RxNorm normalized name: imidapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril 5-20 mg
Trial: 11393342
Drug: Hydrochlorothiazide 12.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5-50 mg
Trial: 3176834
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg/kg i.m. as premedication 45 min before induction with midazolam 0.3 mg/kg i.v. (Group 1)
Trial: 3176834
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg/kg i.m. as premedication 45 min before induction with thiopentone 4 mg/kg (Group 2)
Trial: 3176834
Drug: Calculated i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated i.v. administration curve
Trial: 4753236
Drug: Oxprenolol 40
RxNorm normalized name: oxprenolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 40 mg oral tablet
Trial: 31965548
Drug: Carotegrast methyl
RxNorm normalized name: Carotegrast methyl
DrugBank: Carotegrast methyl (DB16119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotegrast methyl (240, 480, or 960 mg)
Trial: 21304925
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment of malaria (IPTc) with sulphadoxine pyrimethamine plus amodiaquine
Trial: 17090282
Drug: Placebo-to-tegaserod (switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-to-tegaserod (switched from placebo to tegaserod 6 mg b.i.d.)
Trial: 15612887
Drug: SCM‐III 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCM‐III 10 mL t.i.d
Trial: 11035353
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally 48 hours before operation
Trial: 11035353
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally 24 hours before operation
Trial: 8640072
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous thymopentin (TP5) treatment, 1 g three times a week for three patients, 1 g daily for three patients, 2 g daily for two patients
Trial: 8640072
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous thymopentin (TP5) treatment
Trial: 1597660
Drug: Bifidobacterium bifidum
RxNorm normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium bifidum and Lactobacillus acidophilus (Infloran) administered in capsules (two capsules 4 times per day) for 28 days
Trial: 1597660
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in the same posology for 28 days
Trial: 2996156
Drug: Low-dose corticotrophin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticotrophin (ACTH)
Trial: 23129742
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy
Trial: 21999189
Drug: Double-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose group (40 mg/Kg TA before and after CPB)
Trial: 21999189
Drug: Single-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose group (40 mg/Kg TA before CPB and placebo after CPB)
Trial: 21999189
Drug: Double-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose group (TA2)
Trial: 21999189
Drug: Double-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose group
Trial: 18192495
Drug: True iontophoresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True iontophoresis (TI) with a 40‐mA/min dose of iontophoresis using a 0.4% (4 mg/mL) solution of dexamethasone
Trial: 10728173
Drug: Venlafaxine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (75 mg/day) plus CBT
Trial: 10728173
Drug: Fluoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40 mg/day) plus CBT